Crispr Selling General Administrative from 2010 to 2024
| CRSP Stock | USD 51.24 3.91 7.09% |
Selling General Administrative | First Reported 2014-12-31 | Previous Quarter 19.5 M | Current Value 17.4 M | Quarterly Volatility 7.8 M |
Check Crispr Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Crispr Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 20.8 M, Interest Expense of 56.6 M or Selling General Administrative of 62.4 M, as well as many indicators such as Price To Sales Ratio of 12.69, Dividend Yield of 0.0 or PTB Ratio of 2.77. Crispr financial statements analysis is a perfect complement when working with Crispr Therapeutics Valuation or Volatility modules.
Crispr | Selling General Administrative |
Latest Crispr Therapeutics' Selling General Administrative Growth Pattern
Below is the plot of the Selling General Administrative of Crispr Therapeutics AG over the last few years. It is Crispr Therapeutics' Selling General Administrative historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Crispr Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Selling General Administrative | 10 Years Trend |
|
Selling General Administrative |
| Timeline |
Crispr Selling General Administrative Regression Statistics
| Arithmetic Mean | 43,309,597 | |
| Geometric Mean | 24,542,695 | |
| Coefficient Of Variation | 85.78 | |
| Mean Deviation | 32,080,370 | |
| Median | 35,845,000 | |
| Standard Deviation | 37,151,383 | |
| Sample Variance | 1380.2T | |
| Range | 97.7M | |
| R-Value | 0.89 | |
| Mean Square Error | 307.9T | |
| R-Squared | 0.79 | |
| Slope | 7,396,949 | |
| Total Sum of Squares | 19323.2T |
Crispr Selling General Administrative History
About Crispr Therapeutics Financial Statements
Crispr Therapeutics shareholders use historical fundamental indicators, such as Selling General Administrative, to determine how well the company is positioned to perform in the future. Although Crispr Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Crispr Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Crispr Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Selling General Administrative | 76.2 M | 62.4 M |
Pair Trading with Crispr Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Crispr Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Crispr Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Crispr Stock
| 0.53 | VALN | Valneva SE ADR | PairCorr |
| 0.46 | ME | 23Andme Holding | PairCorr |
| 0.34 | DOMH | Dominari Holdings | PairCorr |
| 0.31 | DRRX | Durect | PairCorr |
The ability to find closely correlated positions to Crispr Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Crispr Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Crispr Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Crispr Therapeutics AG to buy it.
The correlation of Crispr Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Crispr Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Crispr Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Crispr Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Crispr Stock Analysis
When running Crispr Therapeutics' price analysis, check to measure Crispr Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crispr Therapeutics is operating at the current time. Most of Crispr Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crispr Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crispr Therapeutics' price. Additionally, you may evaluate how the addition of Crispr Therapeutics to your portfolios can decrease your overall portfolio volatility.